<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">F0111</CoID>
		<CoID Type="CompanyName">Abzena PLC</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">ABZA</IssueID>
			<IssueID Type="CUSIP">G8034U109</IssueID>
			<IssueID Type="ISIN">GB00BN65QN46</IssueID>
			<IssueID Type="RIC">ABZA.L</IssueID>
			<IssueID Type="SEDOL">BN65QN4</IssueID>
			<IssueID Type="DisplayRIC">ABZA.L</IssueID>
			<IssueID Type="InstrumentPI">160827093</IssueID>
			<IssueID Type="QuotePI">160909840</IssueID>
			<Exchange Code="SEA" Country="GBR">SEATS (AIM Market)</Exchange>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2015-09-21</LastModified>
		<LatestAvailableAnnual>2015-03-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2015-03-31</LatestAvailableInterim>
		<Employees LastUpdated="2015-03-31">91</Employees>
		<SharesOut Date="2015-08-07" TotalFloat="59911166.0">97484855.0</SharesOut>
		<ReportingCurrency Code="GBP">British Pounds</ReportingCurrency>
		<MostRecentExchange Date="2015-10-28">0.65531</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2015-07-13T06:58:05">Abzena plc is a life sciences company providing services and technologies. The Company is engaged in the provision of services and technology licenses. The Company consists of PolyTherics and Antitope, which have established a suite of services and technologies that are designed to improve the chances of development of antibodies and proteins with therapeutic benefits. Antitope provides immunogenicity assessment, protein engineering and manufacturing cell line development. The Company's protein engineering technologies, Composite Human Antibodies and Composite Proteins, are used to create products with less risk of producing an unwanted immune response in patients. PolyTherics specializes in site-specific bioconjugation of drugs to therapeutic antibodies and other targeting proteins, which deliver the drug to specific cells, including cancer cells.</Text>
		<Text Type="Financial Summary" lastModified="2015-07-22T08:03:09">BRIEF: For the fiscal year ended 31 March 2015, Abzena PLC revenues increased 50% to L5.7M. Net loss increased 21% to L4.7M. Revenues reflect Europe (excluding United Kingdom) segment increase from L873K to L1.9M, North America segment increase of 50% to L3M. Higher net loss reflects Administrative expenses - Other increase of 34% to L5.6M (expense), Research and development costs increase of 47% to L3M (expense).</Text>
	</TextInfo>
	<contactInfo lastUpdated="2015-09-21T13:03:23">
		<streetAddress line="1">Babraham Hall</streetAddress>
		<streetAddress line="2"></streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>CAMBRIDGE</city>
		<state-region></state-region>
		<postalCode>CB22 3AT</postalCode>
		<country code="GBR">United Kingdom</country>
		<contactName></contactName>
		<contactTitle></contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1223</city-areacode>
				<number>903498</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2014-07-09T08:02:39"><webSite mainCategory="Home Page">http://www.antitope.com</webSite><eMail mainCategory="Company Contact/E-mail"></eMail></webLinks>
	<peerInfo lastUpdated="2015-09-21T13:03:23">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620201010" mnem="">Biotechnology &amp; Medical Research - NEC</Industry>
			<Industry type="NAICS" order="1" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="SIC" order="1" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers></officers>
	<Ratios PriceCurrency="GBP" ReportingCurrency="GBP" ExchangeRate="1.00000" LatestAvailableDate="2015-03-31">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">0.66000</Ratio>
			<Ratio FieldName="NHIG" Type="N">0.87000</Ratio>
			<Ratio FieldName="NLOW" Type="N">0.65000</Ratio>
			<Ratio FieldName="PDATE" Type="D">2015-10-29T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">0.00250</Ratio>
			<Ratio FieldName="EV" Type="N">48.54100</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">64.34000</Ratio>
			<Ratio FieldName="AREV" Type="N">5.66700</Ratio>
			<Ratio FieldName="AEBITD" Type="N">-4.51000</Ratio>
			<Ratio FieldName="ANIAC" Type="N">-4.72200</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="AEPSXCLXOR" Type="N">-0.06594</Ratio>
			<Ratio FieldName="AREVPS" Type="N">0.07913</Ratio>
			<Ratio FieldName="ABVPS" Type="N">0.28572</Ratio>
			<Ratio FieldName="ACSHPS" Type="N">0.16209</Ratio>
			<Ratio FieldName="ACFSHR" Type="N">-0.05492</Ratio>
			<Ratio FieldName="ADIVSHR" Type="N">0.00000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="AGROSMGN" Type="N">55.32028</Ratio>
			<Ratio FieldName="AROEPCT" Type="N">-22.82097</Ratio>
			<Ratio FieldName="APR2REV" Type="N">11.35345</Ratio>
			<Ratio FieldName="APEEXCLXOR" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="APRICE2BK" Type="N">2.30994</Ratio>
			<Ratio FieldName="Employees" Type="N">91</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2016" CurFiscalYearEndMonth="3" CurInterimEndCalYear="2015" CurInterimEndMonth="9" EarningsBasis="REP">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">2</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">0.96500</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">-13.75000</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">6.81270</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">-0.04800</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">-5.27670</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">0.00000</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
